Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : IMDS nasdaq bulletin board -- Ignore unavailable to you. Want to Upgrade?

To: Labrador who wrote (3110)	4/6/1999 9:14:00 AM
From: gao seng	Read Replies (1) \| Respond to of 4122

Scattershooting while wondering whatever happened to the Lintroscan: Interesting post found this morning on the mammogram adjunct market while running my morning SI scan on keyword cancer: Message 8724641 this is what our competition says about thermal imaging....... too bad they are at least a year behind us........ they will be interviewed on cnbc* 4/6 with a segment to show about 2 weeks later.* DYNAMICS IMAGING, INC. 1200 MacArthur Blvd. Mahwah, NJ 07430 Voice: (201) 760 6464 Fax: (201) 760 8860 E-mail: Info@DynamicsImaging.com Early, Non-Invasive Breast Cancer Diagnosis By Accurately Imaging Physiological Anomalies Within The Breast Detecting and Diagnosing Breast Cancer In the United States, every three minutes a woman is diagnosed with breast cancer, totaling nearly 190,000 cases annually. Each year, breast cancer claims the lives of more than 44,000 women and nearly 300 men (some reports indicate this number is nearly 1000). According to the American Cancer Society, more women in the United States are diagnosed with breast cancer every year than with any other cancer. The significant shortcomings which exist today in current breast cancer detection and diagnosis technologies represent a major market opportunity for a new noninvasive and quantitative technology capable of providing significant improvements in the levels of sensitivity (accurate diagnosis of cancerous lesions when cancer is present or true positives) and specificity (accurate diagnosis of benign lesions when cancer is not present or true negatives). An Urgent Need for the Technology With nearly 900 women dying from breast cancer each week in the United States alone, the management and employees of DII have a heightened sense of urgency toward the successful development, approval and introduction of the DOBI technology into the marketplace. In 1997, state of the art mammography was sensitive enough to identify only 80~85% of cancers (i.e., 15~20% false negative results). Studies also indicate that about 100 out of every 10,000 women screened are biopsied, and, of these, only 15~20 confirm cancer, (i.e., the overall false-positive rate is 80~85%) and, hence, did not need a biopsy. This creates a large opportunity for a new, more effective diagnostic and screening technology. Does not expose the patient to radiation as in the case of x-ray mammography. This allows physicians to repeat the test as often as needed, which is especially important for women at high risk for developing breast cancer (such as those who have a predisposing gene or a family history of breast cancer) and other patients requiring multiple follow up examinations. Has the potential of providing the patient and physician with immediate, quantitative test results which indicate the likelihood that a suspicious lesion is malignant (i.e., cancerous) or benign (i.e., harmless) with a high degree of accuracy. In contrast to x-ray mammography, DOBI may be effective in detecting cancer in dense breast tissue as often seen in women below the age of 50. Is non-invasive with all images, and offers a high degree of comfort for patients. Eliminates adverse side effects and complications associated with invasive diagnostic modalities. Eliminates the pain often associated with mammography testing. Has the potential for reducing medical costs for patients and third-party payors by reducing the number of biopsies currently costing the U.S. healthcare system over $2.5 billion each year. Can be performed by a trained physician or medical/mammography technician in approximately 10 to 15 minutes, with immediate feedback available to the medical professional. The anticipated end user purchase price is expected to be significantly less than the cost of ultrasound, MRI, PET or other various diagnostic imaging equipment.